| Literature DB >> 24799496 |
Abstract
Opioids remain the mainstay of severe pain management in patients with cancer. The hallmark of pain management is individualization of therapy. Although almost all clinically used drugs act through mu opioid receptors, they display subtle but important differences pharmacologically. Furthermore, not all patients respond equally well to all drugs. Evidence suggests that these variable responses among patients have a biologic basis and are likely to involve both biased agonism and the many mu opioid receptor subtypes that have been cloned.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24799496 PMCID: PMC4031189 DOI: 10.1200/JCO.2013.53.1079
Source DB: PubMed Journal: J Clin Oncol ISSN: 0732-183X Impact factor: 44.544